Friday, July 10, 2026

Drug profile · INN

apomorphine

apomorphine (APOMINE INTERMITTENT) is a d2-like dopamine receptor agonist. Associated with STADA Pharmaceuticals Australia Pty Limited.

EMA: withdrawn TGA: approved Genito-urinary system and sex hormones (G04) G04BE
Patents linked 14
Pipeline programs 10
News articles 0
Drug details — apomorphine
Class
Genito-urinary system and sex hormones (G04)
Route
Patents
14
Programs
10
Data quality
0.89

Quick answer

apomorphine (APOMINE INTERMITTENT) is a d2-like dopamine receptor agonist. Associated with STADA Pharmaceuticals Australia Pty Limited.

Key facts

INN apomorphine
Brand APOMINE INTERMITTENT
Mechanism D2-like dopamine receptor agonist
Therapeutic class Genito-urinary system and sex hormones (G04)
ATC code G04BE

Mechanism of action

D2-like dopamine receptor agonist

Approval history

Authority Status Date
EMA withdrawn
TGA approved

Pipeline programs

  1. Intermittent hepatic inflow occlusion (IHIO) Phase 3 · Samsung Bioepis · End Stage Liver Disease
  2. M1095-HS-301 Phase 3 · MoonLake Immunotherapeutics · hidradenitis suppurativa (HS)
  3. M1095-HS-302 Phase 3 · MoonLake Immunotherapeutics · hidradenitis suppurativa (HS)
  4. M1095-PSA-301 Phase 3 · MoonLake Immunotherapeutics · Psoriatic arthritis
  5. M1095-PSA-302 Phase 3 · MoonLake Immunotherapeutics · psoriatic arthritis
  6. apomorphine infusion Phase 3 · SUPERNUS PHARMACEUTICALS · Idiopathic Parkinson's Disease
  7. Intermittent Oral Naltrexone Phase 2 · BRIGHT MINDS BIOSCIENCES · Methamphetamine
  8. Intermittent PD-1/PD-L1 ICI + VEGFR-TKI Phase 2 · Chinese Academy of · Renal Cell Carcinoma (RCC)

Related & competitor drugs

  1. mirabegron Genito-urinary system and sex hormones (G04)
  2. oxybutynin Genito-urinary system and sex hormones (G04)
  3. raloxifene Genito-urinary system and sex hormones (G03)
  4. sildenafil Genito-urinary system and sex hormones (G04)
  5. silodosin Genito-urinary system and sex hormones (G04)
  6. tadalafil Genito-urinary system and sex hormones (G04)
  1. US 12383625

    Polyoxazoline-drug conjugates with novel pharmacokinetic properties

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12383626

    Polyoxazoline-drug conjugates with novel pharmacokinetic properties

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 12233132

    Polyoxazoline-lipid conjugates and lipid nanoparticles and pharmaceutical compositions including same

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 11925689

    Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same

    Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11213588

    Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same

    Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 10864276

    Activated polyoxazolines and conjugates and compositions comprising the same

    Expires Mon Dec 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 10166294

    Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same

    Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 10086084

    Activated polyoxazolines and conjugates and compositions comprising the same

    Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 9169354

    Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same

    Expires Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 8501899

    Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same

    Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 8110651

    Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same

    Expires Mon Feb 02 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 8101706

    Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same

    Expires Mon Jan 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 8088884

    Multi-armed forms of activated polyoxazoline and methods of synthesis thereof

    Expires Mon Dec 29 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 7943141

    Activated polyoxazolines and compositions comprising the same

    Expires Mon May 12 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is apomorphine?

apomorphine (APOMINE INTERMITTENT) is a d2-like dopamine receptor agonist. Associated with STADA Pharmaceuticals Australia Pty Limited.

What is the brand name for apomorphine?

APOMINE INTERMITTENT is a marketed brand name for apomorphine. Check FDA Drugs@FDA for the current US label holder and prescribing information.